Epilepsy is a serious neural disease that affects around 50 million people throughout the world. Epilepsy is the term used for a group of disorders characterized by recurrent spontaneous seizures that apparently result from complex processes including several neurotransmitter systems such as the glutamatergic, cholinergic, and GABAergic system. Actual estimations of the prevalence rate for epilepsy are 1–2% of the world population. Epilepsy is common, sudden, and transient episodes (seizures) of loss or disturbance of consciousness. Usually, but not always with the characteristic body movements (convulsions) and sometimes related with autonomic hyperactivity. It correlates with an abnormal electrical discharge.

Although it has a high prevalence among people of all ages, is a serious and diverse set of chronic neurologic disorders characterized by sudden and unexpected occurring seizures. In a recent study, the age-adjusted lifetime prevalence of epilepsy ranged from 2.2 to 41.0 per 1,000 persons, whereas the age-adjusted annual incidence ranged from 16 to as high as 111 per 10,000 persons.

Glutamate is the major excitatory neurotransmitter in the brain, AMPA receptors (AMPARs) represent a validated target for AEDs (antiepileptic drug) development. Evidences support their role during seizures and neurodegeneration.

The ionotropic glutamate receptors are a family of ion channel that are divided into the three subtypes N-methyl aspartate (NMDA), (s)-2-amino-3-(3-hydroxymethyl-4-isoxazoleyl) propionic acid (AMPA), and kainite receptors. The channels are permeable for sodium, potassium and calcium and mediate excitatory

Diseases characterized by recurrent seizures are known as epilepsy. One of the most important mechanisms for handling it is GABA receptor mediated inhibition. In the same context while studying the treatment of epilepsy we observed significant effects by derivatives of sulfonamides, which prompted us to design novel derivatives by means of in silico resources with antiepileptic effects. Molecular docking approaches are routinely used in modern drug design to help understand drug–receptor interaction. This study has been performed with the help of Chemdraw Ultra 7.0, GUSAR online tool for IC50 and LD50 predictions, AutoDock Vina (Python Prescription 0.8), and PaDEL software. Results revealed that ligand-protein interaction affinity of all 10 designed molecules ranges from -5.7 Kcal/mol to -5.2 Kcal/mol, which is approximately comparable to pre-existing GABA inhibitor i.e. phenytoin (CID: 1775, ligand-protein interaction affinity is -6.5 Kcal/mol).

Key words: Quinazolinediones sulphonamide, GABA1, docking, online tools

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

For reprints contact: reprints@medknow.com
synaptic transmission. Over-stimulation of these receptors causes an uncontrolled Ca-influx into the cells resulting in excitotoxicity and possible cell death. Several disorders are at least in part-linked to over activity of iGluRs, such as epilepsy, chronic pain or neuropathology ensuing from cerebral ischemia or cardiac arrest. Different types of antagonists acting at various sites of these receptors were shown to have anticonvulsant, neuroprotective or antinociceptive effects in a range of animal models.

The quinazolinone sulfonamides represent a novel class of competitive AMPA receptor antagonists, displaying nanomolar affinities and providing examples— albeit of lower affinity with oral activity in animal models for anticonvulsant effects. Quinazoline-2,4-diones with a sulfonamide group attached to the N(3) ring atom constitute a novel class of competitive AMPA receptor antagonists. AMPA receptors have been associated to a variety of neurodegenerative and psychiatric diseases such as ischemic brain damage, amyotrophic lateral sclerosis, schizophrenia and epilepsy. Excessive stimulation of the glutamatergic system often plays a role in triggering seizures associated with epilepsy.

The use of in silico methods in drug design has grown significantly in popularity over the past couple of years. This in silico structure-based design is rapidly becoming the lead identification cornerstone of many drug discovery processes. Structure-based in silico methods fall into two main categories—virtual screening and de novo design. The most well-known tools are AutoDock, AutoDock Vina and DOCK3, although there are many different commercially available software programs, each encapsulating slightly different theories of the most accurate way of representing a ligand binding to its receptor. An imbalance between the excitatory and inhibitory neurotransmitters is responsible for seizures. At neuronal level, seizure activity often occurs when glutamatergic excitatory neurotransmitters overrides gamma-aminobutyric acid (GABA) mediated inhibition.

The GABA, since long has been considered to be the principal inhibitory neurotransmitter in the mammalian brain. GABA is one of the main inhibitory neurotransmitters in the brain, interacts with three types of receptors as GABA$_{A}$, GABA$_{B}$ and GABA$_{C}$. GABA$_{A}$ receptors, associated with binding sites for benzodiazepines and barbiturates in the form of a receptor complex, control opening of the chloride channel. When GABA binds to the recognition site on the GABA$_{A}$ receptor complex, the channel is opened and chloride anions enter the neuron, which is finally hyperpolarized.

Voltage-gated sodium channels play a crucial role in regulating the electrical excitability of animal cells, being primarily responsible for the depolarization phase of the action potential. The channel consists of a highly processed subunit that is approximately 260 kDa, and is associated with one or more accessory subunits in certain tissues. Functionally, sodium channels are responsible for the generation and propagation of action potential in excitable cells. In response to membrane depolarization activation of sodium channels allows the rapid influx of Na$^+$ ions leading to upstroke of action potential. During depolarization, sodium channels rapidly get inactivated and sodium ions declines. When membrane potential is repolarised recovery of Na$^+$ influx from inactivated state to closed state and again available to open in response to membrane depolarization.

MATERIALS AND METHODS

For carrying out the study, National Center for Biotechnology Information’s (NCBI) website and Protein Data Bank’s (PDB) website were used as receptor sources. For designing and optimizing the geometry of the derivatives, Chemdraw Ultra 7.0 was used. For antitarget interaction profile prediction and rat acute toxicity prediction, the online service available as Gusar online software has been employed. For docking studies of derivatives, AutoDock Vina molecular docking software has been employed and for descriptor calculations PaDEL software has been used.

Molecule designing and optimization:
The chemical structures of the derivatives (fig. 1) were drawn using ChemDraw Ultra 7.0 and energy minimization of derivatives was achieved with Chem3D Pro of ChemOffice suit for taking energy of each molecule up to its lowest energy state (highest stability). 3D structure of phenytoin (CID: 1775) was retrieved from PubChem compound database at NCBI.
Antitarget interaction profile prediction and rat acute toxicity prediction:
For antitarget interaction profile prediction and rat acute toxicity predictions, the GUSAR online software has been employed which is based on the PASS prediction.

Docking studies:
The docking analysis of quinazolinedione sulfonamide derivatives with GABA₁ was carried out by AutoDock Vina[19]. The incorporation of various algorithms makes it a very good tool, as docking search algorithm is based on evolutionary algorithm. It is an iterative optimization technique inspired by Darwinian evolution theory. Evolutionary algorithm consists of population of individuals, which is exposed to random variation by means of variation operators, like mutation and recombination.

RESULTS AND DISCUSSION
After passing the designed compounds through online predictive software, we have found some interesting results, which are described here. Based on the GUSAR online software results, on an average 8 targets have been found to be effective out of 32 employed targets. As per the requirements, we have selected 1 target to work with out of 8 effective targets i.e. sodium/chloride-dependent GABA transporter and predictive value of their IC50 and mole have been extracted and summarized in the Table 1. After analysing the above table we have found that the IC₅₀ value of the novel designed compounds ranges from 0.6020 to 0.6989.

The acute median lethal doses of novel designed quinazolinedione sulfonamide derivatives (S1 to S10) have been estimated in rats for different route of administration. Difference in LD₅₀ values obtained for different routes suggests that availability of compound for metabolism by liver is a major factor in their toxicity.

In silico prediction of LD₅₀ values for rats with four types of administration (oral, intravenous, intraperitoneal, subcutaneous, inhalation) by GUSAR software are given below (Table 2).

| Code | Activity                                      | Predictive value |
|------|----------------------------------------------|------------------|
| S1   | Sodium- and chloride-dependent GABA transporter 1 antagonist | Log₁₀ (4) 725    |
| S2   | Sodium- and chloride-dependent GABA transporter 1 antagonist | Log₁₀ (4) 990    |
| S3   | Sodium- and chloride-dependent GABA transporter 1 antagonist | Log₁₀ (4) 792    |
| S4   | Sodium- and chloride-dependent GABA transporter 1 antagonist | Log₁₀ (5) 124    |
| S5   | Sodium- and chloride-dependent GABA transporter 1 antagonist | Log₁₀ (5) 092    |
| S6   | Sodium- and chloride-dependent GABA transporter 1 antagonist | Log₁₀ (5) 201    |
| S7   | Sodium- and chloride-dependent GABA transporter 1 antagonist | Log₁₀ (4) 767    |
| S8   | Sodium- and chloride-dependent GABA transporter 1 antagonist | Log₁₀ (4) 802    |
| S9   | Sodium- and chloride-dependent GABA transporter 1 antagonist | Log₁₀ (4) 487    |
| S10  | Sodium- and chloride-dependent GABA transporter 1 antagonist | Log₁₀ (4) 821    |

GABA: Gamma-aminobutyric acid

TABLE 1: QUANTITATIVE PREDICTION OF ANTITARGET INTERACTION PROFILES FOR NOVEL DESIGNED COMPOUNDS (S1-S10)

Fig. 1: Chemical structures of the designed derivatives.
The docking analysis of binding site shows that SER297 and TRP315 could be the catalytic site residue. The protein-ligand interaction affinity of designed inhibitors was given by AutoDock Vina for best pose of novel inhibitors. The best pose ligand-protein interaction affinity of 10 molecules was found to be as -5.6, -5.2, -5.6, -5.4, -5.6, -5.4, -5.7, -5.4, -5.7 and -5.7 Kcal/mol, respectively. Here, negative values for interaction energy would reflect the positive docking approach. Number of hydrogen bonds and other binding details are given in Table 3 and docking image is given in fig. 2.

After analysing the docking results we have found that the interacting amino acids for binding of designed molecules (S1-S10) are serine-297 and tryptophan-315, but when we analyse the interacting amino acids for standard drug that is CID-1775 these

### TABLE 2: PREDICTED RAT ACUTE TOXICITY OF DESIGNED DERIVATIVES

|       | S1  | S2  | S3  | S4  | S5  | S6  | S7  | S8  | S9  | S10 |
|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Rat IP LD50 Log_{10} (mmol/kg) | 320 | 472 | 325 | 560 | 214 | 204 | 77  | 16  | 228 | 352 |
| Rat IV LD50 Log_{10} (mmol/kg) | 228 | 177 | 0   | 217 | 127 | 308 | 168 | 58  | 20  | 50  |
| Rat oral LD50 Log_{10} (mmol/kg) | 372 | 214 | 738 | 340 | 450 | 434 | 402 | 406 | 703 | 389 |
| Rat SC LD50 Log_{10} (mmol/kg) | 709 | 701 | 945 | 750 | 434 | 402 | 703 | 389 | 389 | 389 |
| Rat IP LD50 (mg/kg) | 562,500 | 990,900 | 642,100 | 1,214,000 | 570,000 | 534,700 | 415,500 | 360,900 | 537,000 | 814,100 |
| Rat IV LD50 (mg/kg) | 455,100 | 502,200 | 303,800 | 550,400 | 466,700 | 678,700 | 512,200 | 304,400 | 532,500 | 406,400 |
| Rat oral LD50 (mg/kg) | 372,000 | 214,000 | 1,214,000 | 750,000 | 434,000 | 402,000 | 703,000 | 389,000 | 814,100 | 888,000 |
| Rat SC LD50 (mg/kg) | 1,379,000 | 1,680,000 | 2,677,000 | 1,877,000 | 2,518,000 | 1,094,000 | 1,501,000 | 1,109,000 | 853,800 | 908,100 |

Acute rodent toxicity classification of chemicals by OECD project

|       | S1  | S2  | S3  | S4  | S5  | S6  | S7  | S8  | S9  | S10 |
|-------|-----|-----|-----|-----|-----|-----|-----|-----|-----|-----|
| Rat IP LD50 | Class 5 | Class 5 | Class 5 | Class 5 | Class 5 | Class 4 | Class 4 | Class 5 | Class 5 | Class 5 |
| Rat IV LD50 | Class 5 | Class 5 | Class 5 | Class 5 | Class 5 | Class 5 | Class 5 | Class 5 | Class 5 | Class 5 |
| Rat oral LD50 | Class 4 | Class 4 | Class 4 | Class 4 | Class 4 | Class 4 | Class 4 | Class 4 | Class 4 | Class 4 |
| Rat SC LD50 | Class 5 | Class 5 | Class 5 | Class 5 | Class 5 | Class 5 | Class 5 | Class 5 | Class 4 | Class 4 |

IV: Intravenous, IP: intraperitoneal, SC: subcutaneous, OECD: The Organisation for Economic Co-operation and Development

### TABLE 3: DOCKING RESULTS OF NOVEL DESIGNED QUINAZOLIDINE SULFONAMIDE DERIVATIVES AND PHENYTOIN

| Receptor | Ligand | Affinity kcal/mol | H-bonds | H-binding ligand | H-binding receptor |
|----------|--------|-------------------|---------|------------------|-------------------|
| GABA_A  | S1     | -5.6              | 02      | O 11 Acceptor    | SER297 O 137 Both |
|         | S2     | -5.2              | 02      | O 11 Acceptor    | SER297 O 266 Acceptor |
|         | S3     | -5.6              | 02      | O 11 Acceptor    | SER297 O 266 Acceptor |
|         | S4     | -5.4              | 02      | O 11 Acceptor    | SER297 O 266 Acceptor |
|         | S5     | -5.6              | 02      | O 11 Acceptor    | SER297 O 266 Acceptor |
|         | S6     | -5.4              | 02      | O 11 Acceptor    | SER297 O 266 Acceptor |
|         | S7     | -5.7              | 02      | O 11 Acceptor    | SER297 O 266 Acceptor |
|         | S8     | -5.4              | 02      | O 11 Acceptor    | SER297 O 266 Acceptor |
|         | S9     | -5.7              | 02      | O 11 Acceptor    | SER297 O 266 Acceptor |
|         | S10    | -5.7              | 02      | O 11 Acceptor    | SER297 O 266 Acceptor |
|         | CID 1775 | -6.5              | 02      | O 01 Acceptor    | CYS320 S 313 Donor |
|         |        |                   |         |                  |                   |

GABA: Gamma-aminobutyric acid
are cystein-320 and phenylalanine-316. This implies that novel designed molecules have different binding site as compared to CID-1775.

On docking studies and docking analysis of phenytoin with the GABA$_1$, interacting residues (amino acids) are found as CYS320, PHE316 (fig. 3) as catalytic domain for the GABA$_1$, so, there are possibilities of making it with antiepileptic profile.

On docking analysis, the docked poses of all novel designed quinazolinedione sulfonamide derivatives does not superimposes the phenytoin, a preexisting GABA$_1$ inhibitor which can be clearly seen in fig. 4, but then also the docking analysis shows that they nicely docked with protein in the domain other than the catalytic domain. All 10 novel designed quinazolinedione sulfonamide derivatives have been gone through some descriptor calculation, which are listed in Table 4.

In silico studies of the designed quinazolinedione sulfonamide derivatives proved them to be potential GABA$_1$ inhibitors. Although a systemic biochemical study is necessary to confirm the findings. When designed sulfonamide derivatives were docked with GABA$_1$, then designed molecules were found to be nicely docked, so it could be concluded that these derivatives may be proved the good inhibitors of GABA$_1$ for the antiepileptic activity. On comparing the chemical structure of designed derivatives with phenytoin, a preexisting GABA$_1$ inhibitor; there is no structural similarity found, so it is concluded that this system may proved a novel class of this category.

Financial support and sponsorship:
Nil.

Conflicts of interest:
There are no conflicts of interest.

REFERENCES

1. Zhu HL, Wan JB, Wang YT, Li BC, Xiang C, He J, et al. Medicinal compounds with antiepileptic/anticonvulsant activities. Epilepsia 2014;55:3-16.
2. de Almeida RN, Agra Mde F, Maior FN, de Sousa DP. Essential oils and their constituents: Anticonvulsant activity. Molecules 2011;16:2726-42.
3. Meena M, Lakshmi T. Antiepileptic activity of indigenous herbal extracts – A review. Asian J Pharm Clin Res 2013;6:12-4.
4. Keezer MR, Bouma HK, Wolfson C. The diagnostic accuracy of screening questionnaires for the identification of adults with epilepsy: A systematic review. Epilepsia 2014;55:1772-80.
5. Koller M, Lingenhoehl K, Schmutz M, Vranesic IT, Kallen J, Auberson YP, et al. Quinazolinedione sulfonamides: A novel class of competitive AMPA receptor antagonists with oral activity. Bioorg Med Chem Lett 2011;21:3358-61.
6. Orain D, Other S, Koller M, Carcache DA, Froestl W, Allgeier H, et al. 6-Amino quinazolinedione sulfonamides as orally active competitive AMPA receptor antagonists. Bioorg Med Chem Lett 2012;22:996-9.
7. Heals J. In silico structure-based drug design-shifting the bottleneck. Drug Discov World. 2003:Spring:57-60.
8. Shirish DA. Anticonvulsant activity of roots and rhizomes of Glycyrrhiza glabra. Indian J Pharmacol 2002;34:251-5.
9. Lason W, Chlebicka M, Rejdak K. Research advances in basic mechanisms of seizures and antiepileptic drug action. Pharmacol Rep 2013;65:787-801.
10. Czapinski P, Blaszczyk B, Czuczwar SJ. Mechanisms of action of antiepileptic drugs. Curr Top Med Chem 2005;5:3-14.
11. Goldin AL. Mechanisms of sodium channel inactivation. Curr Opin Neurobiol 2003;13:284-90.
12. Shah KU, Nandkishor M, Singh J, Sharma N, Shyam S. Voltage gated sodium channel blockers: Potential treatment for neuropathic pain. Curr Res Inform Pharm Sci 2010;11:11-6.
13. Mills N. ChemDraw ultra 10.0. J Am Chem Soc 2006;128:13649-50.
14. Lagunin A, Zakharov A, Filimonov D, Poroikov V. QSAR modelling of rat acute toxicity on the basis of PASS prediction. Mol Inform 2011;30:241-50.
15. Ajeet. In silico designing and characterization of amiloride derivatives as ion channel modulator. Med Chem Res 2013;22:1004-10.
16. Ajeet. Trans-disciplinary receptor binding of acyclovir to human phenylalanine hydroxylase: Docking approach. Int J Pharm Pharm Sci 2012;4:182-4.
17. Ajeet, Tripathi L, Kumar P. Designing of novel 6(H)-1,3,4-thiadiazine derivatives as MMP12 inhibitors: A MLR and docking approach. Am J Pharmacol Sci 2013;1:29-34.
18. Yap CW. PaDEL-descriptor: An open source software to calculate molecular descriptors and fingerprints. J Comput Chem 2011;32:1466-74.
19. Trott O, Olson AJ. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010;31:455-61.